Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01403155 | A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 | PHASE1 | COMPLETED | 22 | — | — | May 1, 2011 | Aug 1, 2012 | Sep 13, 2017 | 2 | United States |
Frequency and severity of local and systemic reactogenicity, signs and symptoms, adverse events and serious adverse events.
| Arm | Type | Description |
|---|---|---|
| All subjects | EXPERIMENTAL | All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine) at Day o and Month 3. |
| Name | Type | Description |
|---|---|---|
| INO-3401 + EP | BIOLOGICAL | All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3. |
Inclusion Criteria: * Written informed consent in accordance with institutional guidelines. If required by local law, candidates must also authorize the release and use of protected health information (PHI); * Enrollment in and received at least one vaccination in study FLU-001; * Adults of either ...